Search

Dean Yaw Li

from Scotch Plains, NJ
Age ~62
Get Report
Also known as:
Dean Y Li, Dean V Li, Deany Li, Yaw Lidean, Li Y Dean, Li Dean Yaw
Phone and address:
1615 Ramapo Way, Scotch Plains, NJ 07076
(801) 448-3797
Related to:
Daniel T Cribelar, 63
Connected to:
Ace Li, 63Agnes P Li, 62Ai C LiAiguo Li, 59Ang J Li, 57Anne M Li, 79Anran Li, 35Anya Li, 27Ao L Li, 40Baoguo Li, 67

Dean Li Phones & Addresses

  • 1615 Ramapo Way, Scotch Plains, NJ 07076 (801) 448-3797
  • 1416 Wasatch St, Salt Lake Cty, UT 84108 (801) 582-4617
  • Salt Lake City, UT
  • 173 Cedar St, Wellesley Hills, MA 02481 (781) 237-2385
  • Wellesley, MA
  • Saint Louis, MO

Work

Address: 15 N 2030 E, Salt Lake City, UT 84112 Specialities: Cardiologist

Education

School / High School: Doctor of Medicine

Ranks

Certificate: American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)

Professional Records

License Records

Dean Yaw Li

Address:
Salt Lake City, UT
License #:
357340-8905 - Active
Category:
Physician
Issued Date:
Feb 2, 1999
Expiration Date:
Jan 31, 2018
Type:
Physician/Surgeon CS (Schedule 2-5)

Dean Yaw Li

Address:
Salt Lake City, UT
License #:
357340-1205 - Active
Category:
Physician
Issued Date:
Jun 5, 1998
Expiration Date:
Jan 31, 2018
Type:
Physician & Surgeon

Medicine Doctors

Dean Li Photo 1

Dean Y Li, Salt Lake City UT

View page
Specialties:
Cardiovascular Disease
Cardiology
Work:
Uumc Cardiology
50 N Medical Dr, Salt Lake City, UT 84132
Va Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148
U Of Utah Cardiology Division
30 N 1900 E, Salt Lake City, UT 84132
Education:
Washington University at St. Louis (1990)
Dean Li Photo 2

Dean Y Li, Salt Lake City UT

View page
Specialties:
Cardiologist
Address:
15 N 2030 E, Salt Lake City, UT 84112
50 N Medical Dr, Salt Lake City, UT 84132
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)

Resumes

Resumes

Dean Li Photo 3

Senior Vice President Of Discovery Sciences And Translational Medicine

View page
Location:
30 north East Pl east, Salt Lake City, UT 84102
Industry:
Pharmaceuticals
Work:
Merck
Senior Vice President of Discovery Sciences and Translational Medicine
Merck Research Labs
Senior Vice President of Discovery Biology and Translational Medicine
Merck
Vice President and Head of Translational Medicine
Recursion Pharmaceuticals
Co-Founder
Navigen
Co-Founder
Education:
Washington University School of Medicine In St. Louis 1983 - 1990
Doctor of Medicine, Doctorates, Doctor of Philosophy University of Chicago 1979 - 1983
Bachelors, Chemistry
Skills:
Molecular Biology
Research
Cell Biology
Cell Culture
Biochemistry
Clinical Research
Immunology
Clinical Trials
Cancer
Lifesciences
Neuroscience
Biotechnology
Dean Li Photo 4

Doctor

View page
Location:
Salt Lake City, UT
Industry:
Medical Practice
Work:
University of Utah
Doctor
Dean Li Photo 5

Dean Li

View page
Dean Li Photo 6

Dean Li

View page
Dean Li Photo 7

Dean Li

View page
Location:
United States
Dean Li Photo 8

Dean Li

View page
Location:
United States
Dean Li Photo 9

Dean Li Hempstead, NY

View page
Work:
Thirteen/WNET
New York, NY
Feb 2001 to Feb 2012
Associate Director of Local Corporate Marketing
Allscope Media & Communications
New York, NY
Mar 1999 to Feb 2001
Media Coordinator
Education:
NEW YORK UNIVERSITY
May 1996
Bachelor of Arts in Psychology
College of Arts & Science
Dean Li Photo 10

Dean Li Hempstead, NY

View page
Work:
Thirteen/WNET
New York, NY
Feb 2001 to Feb 2012
Associate Director of Local Corporate Marketing
Allscope Media & Communications
New York, NY
Mar 1999 to Feb 2001
Media Coordinator
Education:
NEW YORK UNIVERSITY
May 1996
Bachelor of Arts in Psychology
College of Arts & Science

Business Records

Name / Title
Company / Classification
Phones & Addresses
Dean Y. Li
Medical Doctor
The University of Utah
Commercial Physical Research College/University
15 N 2030 E, Salt Lake City, UT 84112
(801) 581-4422
Dean Li
Director, President, Secretary
China Media Inc
Dean Y. Li
Vice President Of Research And Development , Vice-President
Hydra Biosciences, Inc
Commercial Physical Research · Pharmaceutical Preparation Mfg
790 Memorial Dr, Cambridge, MA 02139
45 Moulton St, Cambridge, MA 02138
(617) 494-5230, (617) 494-5245
Dean Li
Chief Scientific Officer
NAVIGEN, INC
Commercial Physical Research
383 Colorow Dr, Salt Lake City, UT 84108
(801) 990-2498
Dean Yaw Li
Dean Li MD,PHD
Cardiologist · Internist
30 N 1900 E, Salt Lake City, UT 84132
(801) 581-7715
Dean Li
TUSCARAWAS SCI TECH CORP
Dean Y. Li
Cardiovascular
U-U Cardiology Division
General Medical and Surgical Hospitals, Nsk
50 N Medical Dr, Salt Lake City, UT 84132
PO Box 413033, Salt Lake City, UT 84141

Publications

Us Patents

Transgenic Mouse With Endogenous Endoglin Gene Disruption

View page
US Patent:
6372958, Apr 16, 2002
Filed:
May 25, 2000
Appl. No.:
09/578553
Inventors:
Dean Y. Li - Salt Lake City UT
Mark T. Keating - Salt Lake City UT
Assignee:
The University of Utah Research Foundation - Salt Lake City UT
International Classification:
A01K 67027
US Classification:
800 18, 800 3, 800 22, 800 8, 800 9, 800 21
Abstract:
Transgenic mice are genetically engineered for a deficiency in endoglin production. These mice may have a homozygous or hemizygous disruption of the endogenous endoglin gene. Homozygous mice exhibit a lack of endoglin production. The failure to produce endoglin results in arrested development of the vascular system of the mouse and no survival beyond E11. 5. These mice and cells derived therefrom provide useful reagents for understanding the development and pathology of the mammalian vascular system.

Mice Which Are +/− Or −/− For The Elastin Gene As Models For Vascular Disease

View page
US Patent:
6903244, Jun 7, 2005
Filed:
Feb 26, 1999
Appl. No.:
09/258217
Inventors:
Mark T. Keating - Salt Lake City UT, US
Dean Y. Li - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A01K067/027
A01K067/00
G01N033/00
US Classification:
800 18, 800 13, 800 14, 800 3
Abstract:
Elastin, the main component of arterial extracellular matrix, was thought to have a purely structural role. Consistent with this view, elastin hemizygous mice maintain arterial extensibility by increasing the number of elastic lamellae during development. However, mice lacking elastin die of obstructive arterial pathology. This pathology results from subendothelial proliferation and reorganization of smooth muscle, cellular changes similar to those observed in atherosclerosis. Thus, elastin is a molecular determinant of arterial morphogenesis and likely plays a central role in vascular disease. Mice which are heterozygous and null for the elastin gene have been developed. These mice are extremely useful for screening for drugs useful for treating persons with atherosclerosis, hypertension, SVAS or other vascular diseases.

Elastin-Based Compositions

View page
US Patent:
7125837, Oct 24, 2006
Filed:
Feb 28, 2000
Appl. No.:
09/554996
Inventors:
Mark T. Keating - Chestnut Hill MA, US
Dean Y. Li - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A01N 37/18
A61K 38/00
A61K 39/00
C07K 1/00
A61F 2/06
US Classification:
514 2, 530300, 530350, 4241851, 623 111
Abstract:
The present invention provides screening methods that use organisms or cells that lack function in one or both elastin genes. These methods are useful in identifying drugs for the prevention and treatment of obstructive vascular diseases, such as atherosclerosis, vascular restenosis and transplant arteriopathy. Further, the invention provides pharmaceutical compositions containing elastin-based compositions that are particularly potent regulators of proliferation, differentiation, and migration of smooth muscle cells in vitro and in vivo. These pharmaceutical compositions and related methods are useful in the prevention and treatment of disorders characterized by diminished capacity to regulate smooth muscle cell function.

Mice Which Are +/− Or −/− For The Elastin Gene As Models For Vascular Disease

View page
US Patent:
7301067, Nov 27, 2007
Filed:
Jan 28, 2005
Appl. No.:
11/046006
Inventors:
Mark T. Keating - Chestnut Hill MA, US
Dean Y. Li - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
G01N 33/00
G01N 33/567
C12Q 1/00
A61K 38/00
C07K 1/00
US Classification:
800 3, 800 18, 435 4, 435 721, 530300, 530350
Abstract:
Elastin, the main component of arterial extracellular matrix, was thought to have a purely structural role. Consistent with this view, elastin hemizygous mice maintain arterial extensibility by increasing the number of elastic lamellae during development. However, mice lacking elastin die of obstructive arterial pathology. This pathology results from subendothelial proliferation and reorganization of smooth muscle, cellular changes similar to those observed in atherosclerosis. Thus, elastin is a molecular determinant of arterial morphogenesis and likely plays a central role in vascular disease. Mice which are heterozygous and null for the elastin gene have been developed. These mice are extremely useful for screening for drugs useful for treating persons with atherosclerosis, hypertension, SVAS or other vascular diseases.

Promoting Angiogenesis With Netrin1 Polypeptides

View page
US Patent:
7456151, Nov 25, 2008
Filed:
Jul 14, 2005
Appl. No.:
11/183136
Inventors:
Dean Y. Li - Salt Lake City UT, US
Kye Won Park - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 38/17
A61K 38/16
US Classification:
514 12, 514 2
Abstract:
The present invention provides methods and compositions for modulating proliferation, differentiation, migration, and adhesion of cardiovascular cell types.

Methods For Inhibiting Angiogenesis

View page
US Patent:
8097253, Jan 17, 2012
Filed:
Nov 14, 2008
Appl. No.:
12/271825
Inventors:
Dean Y. Li - Salt Lake City UT, US
Kyle Won Park - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 39/00
C07K 16/00
C07K 16/18
US Classification:
4241391, 4241301, 5303871, 5303879
Abstract:
The present invention provides methods and compositions for modulating proliferation, differentiation, migration, and adhesion of cardiovascular cell types.

Compositions And Methods For Inhibiting Vascular Permeability

View page
US Patent:
8309519, Nov 13, 2012
Filed:
May 19, 2011
Appl. No.:
13/111776
Inventors:
Dean Li - Salt Lake City UT, US
Christopher Jones - Salt Lake City UT, US
Nyall London - Bountiful UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 38/16
A61K 38/17
C07K 14/435
US Classification:
514 133, 514 212, 514 11, 530350
Abstract:
Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in, for example, methods of inhibiting vascular permeability and pathologic angiogenesis, including methods of inhibiting vascular permeability and pathologic angiogenesis induced by specific angiogenic, permeability and inflammatory factors, such as, for example VEGF, bFGF and thrombin. Methods for treating specific diseases and conditions are also provided herein.

Compositions And Methods For Treating Ocular Pathologic Angiogenesis And Vascular Permeability

View page
US Patent:
7994130, Aug 9, 2011
Filed:
Dec 11, 2007
Appl. No.:
12/518730
Inventors:
Dean Li - Salt Lake City UT, US
Christopher Jones - Salt Lake City UT, US
Nyall London - Bountiful UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 38/16
A61K 38/17
C07K 14/435
US Classification:
514 133, 514 212, 514 11, 530350
Abstract:
Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in, for example, methods of inhibiting vascular permeability and pathologic angiogenesis, including methods of inhibiting vascular permeability and pathologic angiogenesis induced by specific angiogenic, permeability and inflammatory factors, such as, for example VEGF, bFGF and thrombin. Methods for treating specific diseases and conditions are also provided herein.
Control profile
Dean Yaw Li from Scotch Plains, NJ, age ~62 Get Report